Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-β for the treatment of anemia in advanced cancer patients undergoing chemotherapy: Open-label, randomized controlled study

Oncologist

Volumn 15, Issue 8, 2010, Pages 894-902

  Macciò, Antonio ^a   Madeddu, Clelia ^b   Gramignano, Giulia ^c   Mulas, Carlo ^a   Sanna, Eleonora ^a   Mantovani, Giovanni ^b  

^a Sirai Hospital   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c NS Bonaria Hospital   (Italy)

Author keywords

Advanced cancer patients; Cachexia; Cancer related anemia; Erythropoietin; Iron; Lactoferrin

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; FERRIC GLUCONATE; FERRITIN; HEMOGLOBIN; IRON; LACTOFERRIN; LATTOGLOBINA; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN BETA; UNCLASSIFIED DRUG;

ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BLADDER CANCER; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GYNECOLOGIC CANCER; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; LEUKOPENIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRIC COMPOUNDS; HEMOGLOBINS; HUMANS; LACTOFERRIN; MALE; NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 77956836074     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0020     Document Type: Article

References (34)

1. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med 2004;116(suppl 7A): 11S-26S.
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
3. Macciò A, Madeddu C, Massa D et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: Role of inflammation in cancer-related anemia. Blood 2005;106: 362-367.
4. Spivak JL. The anaemia of cancer: Death by a thousand cuts. Nat Rev Cancer 2005;5:543-555.
5. Miller CB, Jones RJ, Piantadosi S et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-1692.
6. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639-1647.
7. Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer:Asystemic, quantitative review. Cancer 2001;91:2214-2221.
8. Raj DS. Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum 2009;38:382-388.
9. Buck I, Morceau F, Grigorakaki C et al. Linking anemia to inflammation and cancer: The crucial role of TNFα. Biochem Pharmacol 2009;77:1572-1579.
10. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352:1011-1023.
11. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102:783-788.
12. Andrews NC. Anemia of inflammation: The cytokine-hepcidin link. J Clin Invest 2004;113:1251-1253.
13. Auerbach M, Ballard H, Glaspy J. Clinical update: Intravenous iron for anaemia. Lancet 2007;369:1502-1504.
14. González-Chávez SA, Arévalo-Gallegos S, Rascón-Cruz Q. Lactoferrin: Structure, function and applications. Int J Antimicrob Agents 2009;33: 301.e1-301.e8.
15. Baker HM, Baker EN. Lactoferrin and iron: Structural and dynamic aspects of binding and release. Biometals 2004;17:209-216.
16. Rizzo JD, Somerfield MR, Hagerty KL et al.; American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/ American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-149.
17. Duh MS, Lefebvre P, Fastenau J et al. Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve. The Oncologist 2005;10:438-448.
18. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy- related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
19. Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate significantly improves response to epoetin alpha versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. The Oncologist 2007;12:231-242.
20. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-1618.
21. Pedrazzoli P, Farris A, Del Prete S et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26: 1619-1625.
22. Rodgers GM 3rd, Becker PS, Bennett CL et al.; National Comprehensive Cancer Network. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2008;6:536-564.
23. Cella D, Viswanathan HN, Hays RD et al. Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. Cancer 2008;113:1480-1488.
24. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002;87:1209-1221.
25. Ray-Coquard I, Le Cesne A, Rubio MT et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 1999;17:2840-2846.
26. Lönnerdal B, Bryant A. Absorption of iron from recombinant human lactoferrin in young US women. Am J Clin Nutr 2006;83:305-309.
27. Artym J, Zimecki M, Kuryszko J et al. Lactoferrin accelerates reconstitution of the humoral and cellular immune response during chemotherapyinduced immunosuppression and bone marrow transplant in mice. Stem Cells Dev 2005;14:548-555.
28. Wolf JS, Li G, Varadhachary A et al. Oral lactoferrin results in T celldependent tumor inhibition of head and neck squamous cell carcinoma in vivo. Clin Cancer Res 2007;13:1601-1610.
29. Varadhachary A, Wolf JS, Petrak K et al. Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer 2004;111:398-403.
30. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human erythropoiesis- stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009;373:1532-1542.
31. Handland BK, Longmore GD. Erythroid-stimulating agents in cancer therapy: Potential dangers and biologic mechanisms. J Clin Oncol 2009;27: 4217-4226.
32. Henke M, Laszig R, Rb̈e C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, doubleblind, placebo-controlled trial. Lancet 2003;362:1255-1260.
33. Leyland-Jones B, O'Shaughnessy JA. Erythropoietin as a critical component of breast cancer therapy: Survival, synergistic, and cognitive applications. Semin Oncol 2003;30(suppl 16):174-184.
34. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914-924.